Updates are available Correction dated 2024-05-28
Click to view Correction: https://doi.org/10.1038/s41577-024-01051-3
-
Authors
De Martino, Mara http://orcid.org/0000-0002-3049-6495
Rathmell, Jeffrey C.
Galluzzi, Lorenzo
Vanpouille-Box, Claire http://orcid.org/0000-0001-7213-0670
- License Information
-
More Information
Article History
Accepted: 18 March 2024
First Online: 22 April 2024
Change Date: 28 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41577-024-01051-3
Competing interests
: J.C.R. is a founder and scientific advisory board member of Sitryx Therapeutics. L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo; has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom and the Luke Heller TECPR2 Foundation; and holds Promontory stock options. The other authors declare no competing interests.
